OncoMatch/Clinical Trials/NCT07224971
Impact of Circadian Rhythm on Immunotherapy
Is NCT07224971 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Immunotherapy - PD-1 Blocker for advanced/metastatic nsclc.
Treatment: Immunotherapy - PD-1 Blocker — This study aims to determine whether morning versus afternoon treatment impacts efficacy of (standard of care) immunotherapy in a broad patient population. Patients with any type of advanced/metastatic malignancy are eligible to enroll in this study, as long as first-line anti-PD-1/PD-L1 immunotherapy is on label for their condition. Participants will then be randomized to either the early treatment group (administration must start and conclude by 11:00 AM +1 hour window) or the late treatment group (administration must start after 12:00 PM).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Advanced/metastatic
Prior therapy
Must have received: anti-PD-1 therapy — induction (Cohort B)
have completed up to 4 cycles of induction therapy who have stable disease or responsive disease and for which maintenance anti-PD-1/PD-L1 therapy is on-label either alone or in combination (Cohort B)
Cannot have received: anti-PD-1/PD-L1 therapy
Participant unable to receive anti-PD-1/PD-L1 therapy due to prior allergic reactions to therapy or any therapy ingredients
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify